FDA sets Feb. 26 review of Johnson & Johnson COVID-19 vaccine data
The Food and Drug Administration last night announced that its Vaccines and Related Biological Products Advisory Committee will convene Feb. 26 to discuss the emergency use authorization application by Johnson & Johnson and Janssen Biotech, Inc. for its investigational single-dose COVID-19 vaccine candidate.
The Johnson & Johnson candidate is the third to seek an EUA from the agency; the application follows topline efficacy and safety data culled from a phase 3 trial that showed a 72% effectiveness in the U.S. for preventing moderate-to-severe COVID-19.
Related News Articles
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…
Headline
In time for back-to-school health screenings, AHA Aug. 25 released an infographic on strategies that clinicians and the Centers for Disease Control and…
Headline
Receiving a COVID-19 mRNA vaccine or booster during pregnancy can benefit pregnant people and their newborn infants, according to findings from a federally…